Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Clinical trial NCT04855136 · TERMINATED

Trial details

NCT number: NCT04855136
Sponsor: Celgene
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2021-06-01
Primary completion: 2025-04-25
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.